Navigation Links
Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
Date:4/5/2010

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

The drug, called dalfampridine, is the first therapy for multiple sclerosis that can be taken orally. It is also the first FDA-approved therapy to treat impaired walking, a debilitating symptom of the disease limiting patients' independence and ability to accomplish the most basic tasks of daily living. While other multiple sclerosis drugs work by decreasing the inflammation that causes damage to the central nervous system, dalfampridine is designed to allow conduction of nerve impulses despite the damage.

Research that led to the discovery of dalfampridine's therapeutic value dates back to the 1960s, when Dr. Floyd Davis, then a neurologist in training and later a physician at Rush, became intrigued by an unusual clinical observation: many multiple sclerosis patients fare better when their body temperature is slightly lowered, even by just two- or three-tenths of a degree.

"In multiple sclerosis, the protective myelin sheath that wraps around nerve fibers in the brain and spinal cord is damaged, essentially causing a short circuit," said Davis, who is now retired. "Somehow, lower body temperature enabled the electrical pulse to continue its travel along the nerve fibers. I was completely transfixed by the significance of that fact."

It was important because it showed "that the damaged nerve fibers were not doomed, as previously believed," said Dr. Dusan Stefoski, director of the Rush Multiple Sclerosis Center, who teamed up with Davis in 1978, shortly after completing neurology training at Rush.

Davis launched a series of laboratory studies to understand the mechanism that explained the noticeable improvement in symptoms.

He then looked for a compound that could mimic some of the effects of lower body temperature and learned of 4-aminopyridine, or dalfampridine, which blocks the potassium ion channels in nerve fibers.

"The chemical was commonly used in physiology laboratories where scientists were studying normal nerve conduction, but at the time it was used clinically only by physicians in Bulgaria, then a Communist-block country," Davis said. "They didn't know how it worked, but they used it to help patients recover from anesthesia-induced paralysis more quickly."

In 1983, in a small proof-of-concept study, Davis and Stefoski injected the drug in 11 patients whose motor function and eyesight were impaired because of multiple sclerosis.

"It was stunning," Stefoski said. "After a single intravenous dose, the patients could walk better and see better."

Rush was granted market exclusivity by the FDA under the Orphan Drug Act of 1983 and licensed worldwide rights for dalfampridine first to Ireland-based Elan Corporation and subsequently to Acorda Therapeutics, Inc., located in Hawthorne, New York. This month, Acorda began marketing dalfampridine in the U.S. under the brand name Ampyra.

In two Phase III clinical trials conducted by Acorda, the drug yielded a consistent improvement in walking speed. Walking speed increased by about 25 percent in 35 percent of patients in one trial and in 43 percent of patients in the other, as measured by a standard test called the Timed 25-Foot Walk. Study participants who took the drug also experienced greater leg strength than those who took a placebo.

Stefoski said that although the drug has been approved specifically for the treatment of impaired walking, it also relieves other symptoms of multiple sclerosis, since it restores signal conduction in all the affected nerve fibers.

Multiple sclerosis is a chronic, often disabling autoimmune disease. According to the National Multiple Sclerosis Society, more than 2.5 million people worldwide and 400,000 people in the U.S. have been diagnosed with the disease. Symptoms include, in addition to difficulty walking, but fatigue, lack of balance, and problems with eyesight and memory, and heat sensitivity.

Multiple sclerosis takes several forms. The relapsing remitting form, the most common, is characterized by unpredictable acute attacks followed by periods of months to years of remission, with no new signs of disease. In secondary progressive and primary progressive forms of the disease, there is a steady, permanent neurological decline with no periods of remission. Tests have shown that dalfampridine works for all forms of multiple sclerosis.


'/>"/>

Contact: Sharon Butler
Sharon_Butler@rush.edu
312-942-7816
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
2. FDA Issues Guidance to Help Streamline Medical Device Clinical Trials
3. Clinical course of subepithelial lesions
4. Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial
5. NHLBI funds preclinical tests on devices for infants and children with congenital heart defects
6. Medpedia Launches New Clinical Trial Platform
7. Most Antidepressants Miss Key Target of Clinical Depression
8. Banner Health Systems Adopts Quantros Regulatory Reporting Management (RRM) to Manage Clinical Quality and Performance Data and Support Improvements in Quality of Care
9. Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information
10. European Cancer Organization supports a revision of the EU Clinical Trials Directive
11. Roche and Catalyst Resources Team to Explore RIA Healthcare Collaboration Solutions for Enhanced Clinical Diagnosis and Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... campaign returns for a third time to shed lights on the variety of topics ... and inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in ...
(Date:5/27/2016)... ... May 27, 2016 , ... In ... the many who are unaware of the plight of aphasia. In collaboration with ... the “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met ... bowel cleansing and superiority in , ... of the ascending colon   ... Norgine B.V. today announced new positive data from the phase ... preparation) versus standard 2 litre PEG with ascorbate. The study met ...
(Date:5/24/2016)... May 24, 2016  NxStage Medical, Inc. (Nasdaq: ... on advancing renal care, today announced that Jeffrey ... in the following schedule of investor conferences. Where applicable, ... at http://ir.nxstage.com/ .   ... Conference NY, NY           Friday, June 10, 2016 1:30 ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
Breaking Medicine Technology: